Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Cancer cells often evade cell death, leading to drug resistance, which can involve altered translational control.
• Eukaryotic translation initiation factor 4E (eIF4E) is implicated in lymphomagenesis, drug resistance, and rapamycin response modulation.
• The eIF4F complex, including eIF4E and eIF4A, is crucial for ribosome recruitment during translation initiation.

Purpose of the Study:

• To investigate how dysregulation of translation initiation affects tumor progression and chemosensitivity.
• To identify novel compounds that can modulate translation initiation and impact cancer treatment.

Main Methods:

• Utilized small molecule screening to identify compounds affecting translation initiation.
• Tested cyclopenta[b]benzofuran flavaglines, specifically silvestrol, for their ability to modulate eIF4A activity.
• Evaluated silvestrol's effect on chemosensitivity in a mouse lymphoma model with PTEN inactivation or elevated eIF4E.

Main Results:

• Discovered that cyclopenta[b]benzofuran flavaglines, including silvestrol, inhibit translation initiation by modulating eIF4A activity.
• Silvestrol enhanced chemosensitivity in a mouse lymphoma model.
• Demonstrated that targeting translation initiation can restore drug sensitivity in vivo.

Conclusions:

• Dysregulation of translation initiation significantly impacts tumor progression and drug resistance.
• Modulating eIF4A activity with natural products like silvestrol offers a promising strategy to enhance cancer therapy.
• Targeting the ribosome recruitment phase of translation initiation can restore chemosensitivity and provides a novel therapeutic approach.